贝派地酸与他汀类药物心血管获益的对比研究
基于CLEAR Outcomes试验13,970例他汀不耐受患者,应用CTTC方法学比较贝派地酸与他汀的心血管获益。贝派地酸组主要血管事件发生率为10.1%,安慰剂组为11.7%(HR 0.85;95%CI 0.77-0.94)。按LDL-C每降低1 mmol/L标准化后,贝派地酸HR为0.75(95%CI 0.63-0.90),与他汀CTTC荟萃分析的0.78相近。
要点
- 贝派地酸降低主要血管事件风险,HR 0.85(95%CI 0.77-0.94)。
- 按LDL-C每降低1 mmol/L标准化,贝派地酸HR 0.75(95%CI 0.63-0.90),与他汀的0.78相当。
- 贝派地酸在他汀不耐受患者中的心血管获益与同等LDL-C降幅的他汀治疗相似。
核心结论
- 在给定的LDL-C绝对降幅下,贝派地酸降低心血管风险的程度与他汀相似。
研究设计与样本
- 对CLEAR Outcomes试验中13,970例他汀不耐受患者应用CTTC方法学进行事后分析。
- CTTC主要血管事件终点为冠心病死亡、非致死性心肌梗死、致死或非致死性卒中或冠状动脉血运重建的复合终点。
- 将贝派地酸与安慰剂组间LDL-C差异标准化为1 mmol/L后计算HR。
主要发现
- 贝派地酸组703例(10.1%)发生首次主要血管事件,安慰剂组816例(11.7%),HR 0.85(95%CI 0.77-0.94)。
- 按LDL-C每降低1 mmol/L标准化后,贝派地酸HR为0.75(95%CI 0.63-0.90),与他汀CTTC荟萃分析的率比0.78相近。
- 贝派地酸与他汀在主要冠脉事件、非致死性心肌梗死和冠状动脉血运重建终点上的标准化风险降低相似。
临床怎么用
- 对于他汀不耐受患者,贝派地酸可作为降低LDL-C并减少心血管事件的治疗选择。
- 临床决策中可按LDL-C降低幅度预期贝派地酸的心血管获益,与他汀的每单位LDL-C降幅获益类似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events. OBJECTIVES: This study sought to determine whether the relationship between LDL-C lowering and cardiovascular benefit achieved with bempedoic acid resembles that observed with statins when standardized per unit change in LDL-C. METHODS: To compare the treatment effect of bempedoic acid with statins, the methodology of the Cholesterol Treatment Trialists' Collaboration (CTTC) was applied to outcomes among the 13,970 patients enrolled in the CLEAR Outcomes trial. The CTTC endpoint of "major vascular event" was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal stroke, or coronary revascularization. HRs for CTTC-defined endpoints were normalized to 1 mmol/L differences in LDL-C levels between bempedoic acid and placebo groups. RESULTS: A first major vascular event occurred in 703 (10.1%) patients in the bempedoic acid group and 816 (11.7%) patients in the placebo group (HR: 0.85; 95% CI: 0.77-0.94). When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis. Normalized risk reductions were similar for bempedoic acid and statins for the endpoints of major coronary events, nonfatal myocardial infarction, and coronary revascularization. CONCLUSIONS: Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406).
引用
- Lincoff AM, Ray KK, Sasiela WJ, et al. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs. J Am Coll Cardiol. 2024. PMID: 38960508. doi:10.1016/j.jacc.2024.04.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。